Rituximab- and ocrelizumab-induced early- and late-onset neutropenia in a multiple sclerosis patient

[1]  W. Stevenson,et al.  Severe Delayed-Onset Neutropenia Induced by Ocrelizumab , 2021, The Neurohospitalist.

[2]  T. Berger,et al.  Late-onset neutropenia in a multiple sclerosis patient after first dose ocrelizumab switched from rituximab. , 2020, Multiple sclerosis and related disorders.

[3]  D. Biotti,et al.  Late-onset neutropenia after RITUXIMAB therapy for multiple sclerosis, neuromyelitis optica spectrum disorders and MOG-antibody-associated diseases. , 2020, Multiple sclerosis and related disorders.

[4]  M. Filippi,et al.  Late onset absolute neutropenia associated with ocrelizumab treatment in multiple sclerosis: A case report and review of the literature , 2019, Journal of the Neurological Sciences.

[5]  B. Cohen.  Late-onset neutropenia following ocrelizumab therapy for multiple sclerosis , 2019, Neurology.

[6]  W. Rigby,et al.  Rituximab associated late-onset neutropenia—a rheumatology case series and review of the literature , 2016, Clinical Rheumatology.

[7]  J. Palmblad,et al.  Late-onset neutropenia following rituximab therapy: incidence, clinical features and possible mechanisms , 2011, Expert review of hematology.

[8]  P. Lavori,et al.  Immunoglobulin G Fc receptor FcgammaRIIIa 158 V/F polymorphism correlates with rituximab-induced neutropenia after autologous transplantation in patients with non-Hodgkin's lymphoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  W. Wilson,et al.  B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis. , 2005, Blood.

[10]  A. Grigg,et al.  Delayed‐onset neutropenia associated with rituximab therapy , 2003, British journal of haematology.

[11]  N. Fujii,et al.  The earliest stages of B cell development require a chemokine stromal cell-derived factor/pre-B cell growth-stimulating factor. , 2001, Immunity.

[12]  L. Weiner,et al.  Multiple sclerosis flares associated with recombinant granulocyte colony-stimulating factor , 2000, Neurology.

[13]  D. Brooks,et al.  CD8+, CD57+ T cells from healthy elderly subjects suppress neutrophil development in vitro: implications for the neutropenia of Felty's and large granular lymphocyte syndromes. , 2000, Arthritis and rheumatism.